Mr. Thomas Mehrling reports

HELIX BIOPHARMA CORP. ANNOUNCES VOTING RESULTS FROM ITS ANNUAL GENERAL AND SPECIAL MEETING

Helix BioPharma Corp. has released the voting results from the annual general and special meeting of its shareholders held on Friday, Jan. 30, 2026. A total of 61,885,815 common shares were voted at the meeting, representing 81.03 per cent of Helix's total issued and outstanding shares.

Shareholders voted overwhelmingly in favour of all items of business before the meeting. The four director nominees listed in Helix's management information circular dated Dec. 15, 2025, were re-elected as directors of the company to hold office for the ensuing year or until their successors are elected or appointed. The detailed results of the vote for each director are set out below.

The resolutions to appoint Clearhouse LLP as auditor of Helix BioPharma until the next annual general meeting at a remuneration to be determined by the directors were approved with 99.99 per cent of the votes cast in favour.

The resolution regarding the amendment to the articles of the company to effect a consolidation of the issued and outstanding common shares on the basis of a consolidation ratio selected by the directors of the company of up to five preconsolidation common shares for one postconsolidation common share and to authorize the board to determine the final consolidation ratio at its sole discretion was approved with 99.99 per cent of the votes cast in favour.

A report on all items of business voted at the meeting will be filed on SEDAR+.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company. The company innovates from strength to tackle cancer's biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bioconjugates that score with precision against prevalent CEACAM6-expressing solid tumours. Its lead candidate, tumour defence breaker L-DOS47, is a clinical-stage antibody-enzyme conjugate that neutralizes the microenvironment of common, hard-to-treat solid tumours, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today's front-running anti-cancer therapies. L-DOS47 has completed phase 1b studies in non-small-cell lung cancer with novel strategically designed bispecific ADCs targeting CEACAM6 in discovery.

Helix is listed on the Toronto Stock Exchange under the symbol HBP, on OTC Pink under the symbol HBPCD and on FWB under the symbol HBP0.

We seek Safe Harbor.